search
Back to results

PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis

Primary Purpose

Osteoporosis

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
PTH
Alendronate
Sponsored by
Dennis Black
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoporosis focused on measuring PTH, Alendronate, Parathyroid hormone, Osteoporosis, Postmenopausal

Eligibility Criteria

55 Years - 85 Years (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Aged between 55 and 85 years Postmenopausal (have not had any menses in the last 5 years) Have a bone mineral density scan (DXA) that can be evaluated at the spine AND at the hip with a T-score equal to or below -2.5 at the spine or the femoral neck or total hip OR T-score equal to or below -2.0 at the spine or the femoral neck or total hip and have at least one of the following risk factors for fracture: (a) age > 65 years; (b) history of postmenopausal fracture (nonvertebral or vertebral); or (c) maternal history of hip fracture Willing and able to self-administer daily injections Exclusion Criteria: Have used estrogen (oral or patch) for more than 1 month in the last 6 months or more than 12 months in the last 2 years History of more than 12 months of bisphosphonate use ever, or any use (> 4 weeks) within the past 12 months History of rhPTH (recombinant human PTH) use Any major life-threatening illnesses Type 1 or uncontrolled type 2 diabetes mellitus (defined as hemoglobin A1C > 10.0), or currently using insulin Vitamin D level < 15 nanograms/ml History of kidney disease (creatinine > 2.0 mg/dl) Renal insufficiency (creatinine clearance < 40 mg/min) Any history of kidney stones Any history of hypercalciuria or currently have urine calcium/creatinine >300 mg History of hypercalcemia, sarcoidosis, or hyperparathyroidism History of active or treated tuberculosis or other granulomatous disorders History of breast cancer, melanoma, or hematologic malignancy that has required treatment within the last 10 years History of bone cancer or any other metabolic bone disease that has required treatment within the last 10 years History of any other nonskin cancer that has required treatment within the last 10 years History of symptomatic esophageal reflux, achalasia or esophageal stricture Currently taking > 7.5 mg systemic prednisone or equivalent per day Currently using > two puffs, four times/day of inhaled steroids Currently taking anticoagulants or anticonvulsants Have used Calcitonin within the past 3 months Have used Raloxifene in the last 6 months or for more than 12 months in the last 2 years Have used Tamoxifen in the last 6 months or for more than 12 months in the last 2 years Have used fluoride for at least a month within the past 5 years Currently taking > 1000 IU/day vitamin D or vitamin D analogues or metabolites Currently taking thyroid hormone replacement AND have a TSH < 0.1mIU/L

Sites / Locations

  • Maine Center for Osteoporosis
  • University of Minnesota
  • Columbia University
  • University of Pittsburgh Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Arm Label

1

2

3

4

Arm Description

Participants will receive PTH for 1 year followed by alendronate for 1 year.

Participants will receive PTH and alendronate for 1 year followed by alendronate for 1 year.

Participants will receive alendronate for 2 years.

Participants will receive PTH for 1 year followed by placebo for 1 year.

Outcomes

Primary Outcome Measures

Changes in bone mineral density at several sites and changes in biochemical markers

Secondary Outcome Measures

Predictive value of specific biochemical markers of bone turnover

Full Information

First Posted
March 24, 2000
Last Updated
February 4, 2013
Sponsor
Dennis Black
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
search

1. Study Identification

Unique Protocol Identification Number
NCT00005005
Brief Title
PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
Official Title
Clinical Trial of Parathyroid Hormone (PTH) and Alendronate in Combination in the Treatment of Osteoporosis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
October 1999 (undefined)
Primary Completion Date
November 2007 (Actual)
Study Completion Date
November 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dennis Black
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

4. Oversight

5. Study Description

Brief Summary
This 2-year study will test the effectiveness of combining parathyroid hormone (PTH) and alendronate for treating osteoporosis in postmenopausal women. Alendronate is a drug used to treat osteoporosis and primarily prevents bone loss, whereas PTH increases bone formation. We will treat the study participants either with PTH and alendronate, alendronate alone, or PTH alone. We will determine the effects of these treatments by looking for changes in bone mineral density in the hip and spine.
Detailed Description
The PaTH study is a 2-year, multicenter, double-blind, placebo-controlled trial to test the efficacy of combining hPTH (1-84) and alendronate for treating osteoporosis in postmenopausal women. 238 women were randomized between 55 and 85 years of age to receive either: (1) PTH for 1 year followed by alendronate for 1 year; (2) PTH and alendronate for 1 year followed by alendronate for 1 year; (3) alendronate for 2 years; or (4) PTH for 1 year followed by placebo for 1 year. The primary endpoints are changes in bone mineral density at several sites and changes in biochemical markers. In addition, we will assess specific biochemical markers of bone turnover (e.g., osteocalcin, deoxypridinoline, N-telopeptide, bone-specific alkaline phosphatase and bone sialoprotein) to determine if they can predict the skeletal response to combination therapy. We will also determine whether PTH positively affects ultrasound measurements in the calcaneus.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoporosis
Keywords
PTH, Alendronate, Parathyroid hormone, Osteoporosis, Postmenopausal

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
238 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Participants will receive PTH for 1 year followed by alendronate for 1 year.
Arm Title
2
Arm Type
Experimental
Arm Description
Participants will receive PTH and alendronate for 1 year followed by alendronate for 1 year.
Arm Title
3
Arm Type
Experimental
Arm Description
Participants will receive alendronate for 2 years.
Arm Title
4
Arm Type
Active Comparator
Arm Description
Participants will receive PTH for 1 year followed by placebo for 1 year.
Intervention Type
Drug
Intervention Name(s)
PTH
Intervention Type
Drug
Intervention Name(s)
Alendronate
Primary Outcome Measure Information:
Title
Changes in bone mineral density at several sites and changes in biochemical markers
Time Frame
Year 2
Secondary Outcome Measure Information:
Title
Predictive value of specific biochemical markers of bone turnover
Time Frame
Year 2

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Aged between 55 and 85 years Postmenopausal (have not had any menses in the last 5 years) Have a bone mineral density scan (DXA) that can be evaluated at the spine AND at the hip with a T-score equal to or below -2.5 at the spine or the femoral neck or total hip OR T-score equal to or below -2.0 at the spine or the femoral neck or total hip and have at least one of the following risk factors for fracture: (a) age > 65 years; (b) history of postmenopausal fracture (nonvertebral or vertebral); or (c) maternal history of hip fracture Willing and able to self-administer daily injections Exclusion Criteria: Have used estrogen (oral or patch) for more than 1 month in the last 6 months or more than 12 months in the last 2 years History of more than 12 months of bisphosphonate use ever, or any use (> 4 weeks) within the past 12 months History of rhPTH (recombinant human PTH) use Any major life-threatening illnesses Type 1 or uncontrolled type 2 diabetes mellitus (defined as hemoglobin A1C > 10.0), or currently using insulin Vitamin D level < 15 nanograms/ml History of kidney disease (creatinine > 2.0 mg/dl) Renal insufficiency (creatinine clearance < 40 mg/min) Any history of kidney stones Any history of hypercalciuria or currently have urine calcium/creatinine >300 mg History of hypercalcemia, sarcoidosis, or hyperparathyroidism History of active or treated tuberculosis or other granulomatous disorders History of breast cancer, melanoma, or hematologic malignancy that has required treatment within the last 10 years History of bone cancer or any other metabolic bone disease that has required treatment within the last 10 years History of any other nonskin cancer that has required treatment within the last 10 years History of symptomatic esophageal reflux, achalasia or esophageal stricture Currently taking > 7.5 mg systemic prednisone or equivalent per day Currently using > two puffs, four times/day of inhaled steroids Currently taking anticoagulants or anticonvulsants Have used Calcitonin within the past 3 months Have used Raloxifene in the last 6 months or for more than 12 months in the last 2 years Have used Tamoxifen in the last 6 months or for more than 12 months in the last 2 years Have used fluoride for at least a month within the past 5 years Currently taking > 1000 IU/day vitamin D or vitamin D analogues or metabolites Currently taking thyroid hormone replacement AND have a TSH < 0.1mIU/L
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dennis Black, PhD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maine Center for Osteoporosis
City
Bangor
State/Province
Maine
ZIP/Postal Code
04401
Country
United States
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55415
Country
United States
Facility Name
Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
14500804
Citation
Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1207-15. doi: 10.1056/NEJMoa031975. Epub 2003 Sep 20.
Results Reference
result
PubMed Identifier
16093464
Citation
Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005 Aug 11;353(6):555-65. doi: 10.1056/NEJMoa050336.
Results Reference
result
PubMed Identifier
16449339
Citation
Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006 Apr;91(4):1370-5. doi: 10.1210/jc.2005-1712. Epub 2006 Jan 31.
Results Reference
result
PubMed Identifier
17333451
Citation
Sellmeyer DE, Black DM, Palermo L, Greenspan S, Ensrud K, Bilezikian J, Rosen CJ. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos Int. 2007 Jul;18(7):973-9. doi: 10.1007/s00198-007-0336-x. Epub 2007 Feb 28.
Results Reference
result
PubMed Identifier
17164314
Citation
Antoniucci DM, Sellmeyer DE, Bilezikian JP, Palermo L, Ensrud KE, Greenspan SL, Black DM. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J Clin Endocrinol Metab. 2007 Mar;92(3):942-7. doi: 10.1210/jc.2006-1788. Epub 2006 Dec 12.
Results Reference
result

Learn more about this trial

PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis

We'll reach out to this number within 24 hrs